By Max Braht, Director of Business Development, LSN
At RESI Boston June 2025, 53 companies participated in the Innovator’s Pitch Challenge (IPC), presenting their technologies to panels of active investors and showcasing their work in the Exhibition Hall. RESI attendees — including early-stage investors, startup executives, and industry leaders — voted for the most impressive companies based on pitch presentations, Q&A performance, and networking in the exhibit hall.
Congratulations to the Top-Ranked IPC Companies from RESI Boston June
First Place: MindLab
Our lead product, MLB-001, is a first-in-class, combination drug designed to deliver powerful, life-changing pain relief using significantly lower morphine doses. MLB-001 achieves equal or superior analgesic effects compared to conventional morphine, while minimizing common side effects and reducing the development of drug tolerance. Importantly, MLB-001 is specifically engineered to lower the risk of addiction, a critical advancement given the ongoing opioid crisis. MindLab is committed to redefining pain care by introducing safer, more effective treatments that address unmet medical needs and promote better quality of life for patients worldwide.
Sougato Das, President and COO, Life Science Nation | Larry Raoul James JD, MBA, Founder, President, and CEO of MindLab | Dennis Ford, Founder & CEO, Life Science Nation
Second Place: Inomagen Therapeutics
Inomagen Therapeutics, Inc. is a private, preclinical stage biotechnology company pioneering a gene therapy to improve the treatment of atrial fibrillation. Inomagen has intellectual property and proof of concept data for both the gene and the gene delivery system. Inomagen has a strong and experienced team of industry veterans and key opinion leading cardiovascular physicians to engage in management and advisory roles, including those with extensive domain experience in gene therapy, cardiology, AF therapeutics, medical device, clinical studies, and venture capital. The market size for Inomagen’s gene therapy products is $10.2B.
Sougato Das, President and COO, Life Science Nation | Eric Sandberg, CBO, Inomagen Therapeutics | Robin Drassler, VP of Business Development, Inomagen Therapeutics | Dennis Ford, Founder & CEO, Life Science Nation
Third Place: MantaBio
MantaBio is a life sciences tools company building automated microbial detection systems specifically designed for biopharma manufacturing environments. Our platform offers rapid, high-sensitivity detection across all microbe categories: bacteria, fungi, viruses, and mycoplasma — delivering results in just 2 hours compared to the industry standard of 5 to 28 days. Built with the needs of biologics producers in mind, MantaBio’s technology is optimized for speed, accuracy, and ease of use. It requires less than one minute of hands-on time, no specialized training, and integrates seamlessly into GMP workflows. By enabling at-line or near-line testing with gold-standard sensitivity, MantaBio helps manufacturers reduce contamination risk, minimize batch loss, and accelerate product release timelines. Our system is the next generation in microbial quality control — replacing outdated manual culture methods and reliance on off-site reference labs with a modern, automated approach built to match the pace and complexity of today’s biopharma processes.
Sougato Das, President and COO, Life Science Nation | Max Braht, Director of Business Development, Life Science Nation | Carter Boisfontaine, Co-Founder and President, MantaBio | Dr. Jack Regan, Co-Founder, CEO, and CTO, MantaBio | Claire Jeong, CCO, Vice President of Investor Research, Asia BD, Life Science Nation | Dennis Ford, Founder & CEO, Life Science Nation
We applaud all IPC participants for sharing their innovative work and contributing to a dynamic, high-impact event.
Applications Now Open for the September IPC at RESI Boston
The Innovator’s Pitch Challenge at RESI Boston September offers life science startups the opportunity to present directly to a curated panel of active investors and receive real-time, constructive feedback. Each pitch includes a live Q&A with investor judges and extended exposure through participation in the IPC exhibition hall.
New for September, the IPC package now includes the option to add a second three-day standard ticket at no additional cost. This provides a teammate with full access to partnering and conference sessions.
Benefits include:
- Investor feedback during live pitch sessions
- Full access to one-on-one partnering
- Exhibit table in the IPC Hall
- Optional additional RESI pass included
Apply now to secure your spot and connect with global early-stage investors this September.
| Apply to Pitch at RESI Boston Sept. 2025 |
Next Phase Newsletter 
Leave a comment